Remicade carries a Boxed Warning for risk of serious infections and cancer.
Remicade有一个对严重感染和癌症风险的黑框警告。
Remicade belongs to a class of drugs called tumor necrosis factor (TNF) blockers.
Remicade属于被称为肿瘤坏死因子(TNF)阻断剂类药物。
Remicade reduces signs and symptoms of uc and induces and maintains clinical remission in these patients.
在这些患者中remicade减轻uc的征象和症状并且诱发及维持临床缓解。
The most common side effects of Remicade are worsening of UC, upper respiratory infections, infusion-related reactions, and headache.
类克最常见的副作用为UC恶化、上呼吸道感染、注射相关感染和头痛。
Children should have all of their vaccines brought up to date before starting treatment with Remicade and should not receive live vaccines while taking Remicade.
在开始用Remicade治疗前儿童应使用他们迄今所有疫苗而用Remicade时不应接受活疫苗。
Among these patients, 69% achieved remission with the combination treatment compared to 57% of those on Remicade alone and to 28% of those on azathioprine alone.
这些病人中，通过联合治疗的有69%的人获得缓解而在英夫利昔单抗组中为57%，硫唑嘌呤组中只有28%的到缓解。
After 26 weeks of treatment, patients getting the combination had a 57% chance of disease remission, compared to 44% of those getting Remicade alone and to 30% of those getting azathioprine alone.
经过26周的治疗，联合用药的病人中有57%获得缓解，与之相比，在单用英夫利昔单抗组中只有44%而单用硫唑嘌呤组中只有30%得到缓解。
After 26 weeks of treatment, patients getting the combination had a 57% chance of disease remission, compared to 44% of those getting Remicade alone and to 30% of those getting azathioprine alone.
经过26周的治疗，联合用药的病人中有57%获得缓解，与之相比，在单用英夫利昔单抗组中只有44%而单用硫唑嘌呤组中只有30%得到缓解。
应用推荐